Literature DB >> 11673319

Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis.

S Cepok1, M Jacobsen, S Schock, B Omer, S Jaekel, I Böddeker, W H Oertel, N Sommer, B Hemmer.   

Abstract

Multiple sclerosis is a chronic inflammatory and demyelinating disease of the CNS with, as yet, an unknown aetiology. Temporal profile, intensity and treatment responses are highly variable in multiple sclerosis suggesting pathogenetic heterogeneity. This hypothesis has been supported by histopathological studies disclosing at least four different subtypes of acute demyelinating lesions. Although stratification of multiple sclerosis patients into these categories would be extremely helpful for clinical studies, this approach is impractical as it requires brain biopsy. In this study we investigated CSF cytology from 60 multiple sclerosis patients by flow cytometry. We identified different patterns of CSF cytology, which were independent of immunological parameters in the peripheral blood. The most variable CSF parameter was the B cell to monocyte ratio, which remained stable during different phases of disease in selected patients. The ratio correlated with disease progression but not with disability or disease duration in a retrospective, consecutive analysis. A high ratio (predominance of B cells) was associated with more rapid disease progression, whereas a low ratio (predominance of monocytes) was found in patients with slower progression. Our study demonstrates the existence and potential clinical relevance of different CSF cytology patterns. We hypothesize that CSF cytology patterns may reflect the heterogeneity in the pathogenesis of multiple sclerosis.

Entities:  

Mesh:

Year:  2001        PMID: 11673319     DOI: 10.1093/brain/124.11.2169

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  78 in total

1.  Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells.

Authors:  Trygve Holmøy; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-02       Impact factor: 2.643

Review 2.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 3.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Characterization of a severe parenchymal phenotype of experimental autoimmune encephalomyelitis in (C57BL6xB10.PL)F1 mice.

Authors:  Michael D Carrithers; Lisette M Carrithers; Jan Czyzyk; Octavian Henegariu
Journal:  J Neuroimmunol       Date:  2007-05-18       Impact factor: 3.478

Review 5.  Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Authors:  B Gomez-Mancilla; E Marrer; J Kehren; A Kinnunen; G Imbert; R Hillebrand; M Bergström; M E Schmidt
Journal:  NeuroRx       Date:  2005-10

Review 6.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

7.  Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis.

Authors:  Kristina M Harris; Noha Lim; Paul Lindau; Harlan Robins; Linda M Griffith; Richard A Nash; Laurence A Turka; Paolo A Muraro
Journal:  JCI Insight       Date:  2020-01-30

8.  Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein.

Authors:  Trygve Holmøy; Espen Østhagen Kvale; Frode Vartdal
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

Review 9.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

10.  B cells as a target of immune modulation.

Authors:  Kathleen Hawker
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.